Annexon (ANNX) Research & Development (2019 - 2026)
Annexon (ANNX) posted quarterly Research & Development of $35.8 million for Q1 2026, down 25.72% year-over-year from $48.2 million in Q1 2025, and down 16.11% quarter-over-quarter from $42.7 million in Q4 2025.
Annexon (ANNX) Research & Development (2019 - 2026) Analysis & Trends
Annexon's Research & Development history runs 8 years deep, the most recent figure standing at $35.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 25.72% year-over-year to $35.8 million; the TTM figure through Mar 2026 stood at $172.3 million (up 17.48% YoY), while the FY2025 annual figure was $184.7 million, up 54.63% from the prior year.
- Research & Development for Q1 2026 stood at $35.8 million, down from $42.7 million in the prior quarter.
- The five-year high for Research & Development was $49.7 million in Q3 2025, with the low at $21.0 million in Q1 2024.
- The 5-year median for Research & Development is $30.1 million (2024), against an average of $33.3 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development plunged 35.19% in 2024, then soared 129.83% in 2025.
- Annexon's Research & Development stood at $28.5 million in 2022, then slipped by 18.46% to $23.3 million in 2023, then jumped by 86.33% to $43.4 million in 2024, then dropped by 1.6% to $42.7 million in 2025, then retreated by 16.11% to $35.8 million in 2026.
- Business Quant data shows ANNX's Research & Development at $35.8 million in Q1 2026, $42.7 million in Q4 2025, and $49.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 46.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.59 Mn |
| Mar 31, 2026 | 35.79 Mn |
| Dec 31, 2025 | 42.66 Mn |
| Sep 30, 2025 | 49.70 Mn |
| Jun 30, 2025 | 44.16 Mn |
| Mar 31, 2025 | 48.18 Mn |
| Dec 31, 2024 | 43.35 Mn |
| Sep 30, 2024 | 30.11 Mn |
| Jun 30, 2024 | 25.03 Mn |
| Mar 31, 2024 | 20.96 Mn |
| Dec 31, 2023 | 23.27 Mn |
| Sep 30, 2023 | 27.89 Mn |
| Jun 30, 2023 | 30.25 Mn |
| Mar 31, 2023 | 32.35 Mn |
| Dec 31, 2022 | 28.54 Mn |
| Sep 30, 2022 | 27.86 Mn |
| Jun 30, 2022 | 29.11 Mn |
| Mar 31, 2022 | 27.00 Mn |
| Dec 31, 2021 | 27.22 Mn |
| Sep 30, 2021 | 27.58 Mn |